AbbVie to buy Botox maker Allergan for $63 billion
The acquisition aims to diversify AbbVie beyond its top-selling drug Humira, which will soon lose patent protection (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - June 25, 2019 Category: Consumer Health News Source Type: news

AbbVie to Acquire Allergan in Transformative Move for Both Companies
Provides immediate scale and profitability to AbbVie's growth platform, excluding Humira, significantly expanding and diversifying its revenue base with new therapeutic areas, including Allergan's leading medical aesthetics business Enhances long-term R... Biopharmaceuticals, Mergers & Acquisitions AbbVie, Allergan (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 25, 2019 Category: Pharmaceuticals Source Type: news

Botox Maker Allergan Is Sold to AbbVie in $63 Billion Deal
The transaction would give AbbVie a potent source of popular treatments as it faces the loss of patent protection for its best-selling drug, Humira. (Source: NYT Health)
Source: NYT Health - June 25, 2019 Category: Consumer Health News Authors: Michael J. de la Merced Tags: Allergan Inc Mergers, Acquisitions and Divestitures Drugs (Pharmaceuticals) AbbVie Inc Botox (Drug) Source Type: news

Lilly Presents Positive Results for Taltz(R) (ixekizumab) vs. Humira(R) (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis at the European Congress of Rheumatology
INDIANAPOLIS, June 14, 2019 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today that the company will present positive findings from the Phase 3b/4 SPIRIT-Head-to-Head (H2H) study in patients with active psoriati... Biopharmaceuticals Eli Lilly, psoriatic arthritis, Taltz, ixekizumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 14, 2019 Category: Pharmaceuticals Source Type: news

On The Toxicity Of Humira And Other Rheumatoid Arthritis Drugs
But articles that trumpet 34,000 deaths on important medicines, that denigrate the FDA ’s approval process and that suggest these drugs shouldn’t be on the market, don’t really help the discussion. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - June 4, 2019 Category: Pharmaceuticals Authors: John LaMattina, Contributor Source Type: news

Long-Term Safety and Efficacy of ABP 501 in Patients With RA Long-Term Safety and Efficacy of ABP 501 in Patients With RA
How does the safety and efficacy of the adalimumab biosimilar ABP 501 compare with that of the reference product?Arthritis Research & Therapy (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - May 31, 2019 Category: Allergy & Immunology Tags: Rheumatology Journal Article Source Type: news

What ’s the Latest in Drug-Delivery Devices?
To simplify drug delivery for patients and practitioners, drug-delivery devices are becoming more complex. Many of today’s devices include special features designed to ease self-dosing and encourage patient adherence with novel regimens. Wearable devices are further easing use by promoting active lifestyles. And some devices are offering connectivity to support digital health monitoring. With so many possibilities, where do device developers and pharmaceutical companies begin? MD+DI asked Eric Resnick, vice president and chief technology officer, innovation and technology, West Pharmaceutical Services Inc...
Source: MDDI - May 22, 2019 Category: Medical Devices Authors: Daphne Allen Tags: Packaging Source Type: news

Boehringer Ingelheim announces resolution of Cyltezo(R) patent litigation
Settlement provides Boehringer Ingelheim with a clear path to secure patient access to Cyltezo® in the U.S. License period places Boehringer Ingelheim's biosimilar among the first to compete with Humira® in the U.S. RIDGEFIELD, Conn., May 14,... Biopharmaceuticals, Litigation, Licensing Boehringer Ingelheim, AbbVie, Cyltezo, adalimumab, biosimilar, Humira (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 14, 2019 Category: Pharmaceuticals Source Type: news

AbbVie Resolves HUMIRA(R) (adalimumab) U.S. Patent Litigation with Boehringer Ingelheim
NORTH CHICAGO, Ill., May 14, 2019 -- (Healthcare Sales & Marketing Network) -- AbbVie (NYSE: ABBV) announced that it has resolved U.S. HUMIRA (adalimumab) litigation with Boehringer Ingelheim (BI). Under the terms of the resolution, AbbVie will grant BI a... Biopharmaceuticals, Litigation, Licensing AbbVie, Boehringer Ingelheim, HUMIRA, adalimumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 14, 2019 Category: Pharmaceuticals Source Type: news

AbbVie raises forecasts despite pressure on Humira
Blockbuster drug’s revenue outside US takes hit from new competition (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - April 25, 2019 Category: Pharmaceuticals Source Type: news

AbbVie's Skyrizi drug to treat psoriasis wins U.S. approval
AbbVie Inc said on Tuesday that the U.S. Food and Drug Administration approved its Skyrizi drug as a treatment for plaque psoriasis at a time when its blockbuster psoriasis drug, Humira, faces patent pressures. (Source: Reuters: Health)
Source: Reuters: Health - April 23, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Predicting Flare Risk After Stopping Adalimumab in RA Predicting Flare Risk After Stopping Adalimumab in RA
A new study examines the question of whether adalimumab trough and antidrug antibody levels predict flare among rheumatoid arthritis patients who have stopped adalimumab.Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 10, 2019 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Why Does Medicine Cost So Much? Here ’s How Drug Prices Are Set
From 2007 to 2016, Mylan raised the list price of its EpiPen about 500%, from just under $100 to more than $600. From 2002 to 2013, insulin prices more than tripled. From 2012 to 2019, the average price of AbbVie’s rheumatoid-arthritis drug Humira climbed from $19,000 a year to $60,000 a year—and that’s after rebates. These are dramatic examples of a systemwide problem: prices for brand-name drugs are rising at a rate that far outstrips inflation. What’s behind these rapid price hikes? It’s a simple question with a complicated answer that involves three central entities: drug manufacturers, ph...
Source: TIME: Health - April 9, 2019 Category: Consumer Health News Authors: Laura Entis Tags: Uncategorized medicine Source Type: news

Drug Survival Rates Highest for Ustekinumab for Pediatric Psoriasis
THURSDAY, March 28, 2019 -- In real-life conditions, drug survival rates are higher for ustekinumab than for adalimumab and etanercept for all treatments and types of psoriasis in children, according to a study published online March 18 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 28, 2019 Category: Pharmaceuticals Source Type: news

AbbVie ’s next potential blockbuster wins approval in Japan
With AbbVie ’s top-selling Humira headed for the patent cliff, the company is gaining momentum for a global rollout of its next potential blockbuster. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - March 27, 2019 Category: Pharmaceuticals Source Type: news